ENVVENO MEDICAL CORP (NVNO) Fundamental Analysis & Valuation

NASDAQ:NVNO • US29415J2050

11.98 USD
+0.52 (+4.54%)
Last: Mar 9, 2026, 02:44 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NVNO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NVNO. NVNO was compared to 184 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NVNO as it has an excellent financial health rating, but there are worries on the profitability. NVNO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. NVNO Profitability Analysis

1.1 Basic Checks

  • In the past year NVNO has reported negative net income.
  • NVNO had a negative operating cash flow in the past year.
  • NVNO had negative earnings in each of the past 5 years.
  • In the past 5 years NVNO always reported negative operating cash flow.
NVNO Yearly Net Income VS EBIT VS OCF VS FCFNVNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • NVNO's Return On Assets of -67.89% is on the low side compared to the rest of the industry. NVNO is outperformed by 72.28% of its industry peers.
  • NVNO has a Return On Equity (-74.59%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -67.89%
ROE -74.59%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
NVNO Yearly ROA, ROE, ROICNVNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

  • NVNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVNO Yearly Profit, Operating, Gross MarginsNVNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NVNO Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, NVNO has more shares outstanding
  • NVNO has more shares outstanding than it did 5 years ago.
  • NVNO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NVNO Yearly Shares OutstandingNVNO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
NVNO Yearly Total Debt VS Total AssetsNVNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • NVNO has an Altman-Z score of -7.02. This is a bad value and indicates that NVNO is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -7.02, NVNO is doing worse than 74.46% of the companies in the same industry.
  • There is no outstanding debt for NVNO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.02
ROIC/WACCN/A
WACCN/A
NVNO Yearly LT Debt VS Equity VS FCFNVNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • NVNO has a Current Ratio of 13.12. This indicates that NVNO is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of NVNO (13.12) is better than 97.83% of its industry peers.
  • A Quick Ratio of 13.12 indicates that NVNO has no problem at all paying its short term obligations.
  • NVNO has a better Quick ratio (13.12) than 98.37% of its industry peers.
Industry RankSector Rank
Current Ratio 13.12
Quick Ratio 13.12
NVNO Yearly Current Assets VS Current LiabilitesNVNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NVNO Growth Analysis

3.1 Past

  • NVNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1412.78%.
EPS 1Y (TTM)-1412.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2200%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NVNO will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.86% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.26%
EPS Next 2Y9.4%
EPS Next 3Y12.02%
EPS Next 5Y12.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVNO Yearly Revenue VS EstimatesNVNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2026 2027 2028 5M 10M 15M 20M 25M
NVNO Yearly EPS VS EstimatesNVNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. NVNO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NVNO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVNO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVNO Price Earnings VS Forward Price EarningsNVNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVNO Per share dataNVNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NVNO's earnings are expected to grow with 12.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.4%
EPS Next 3Y12.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NVNO Dividend Analysis

5.1 Amount

  • No dividends for NVNO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NVNO Fundamentals: All Metrics, Ratios and Statistics

ENVVENO MEDICAL CORP

NASDAQ:NVNO (3/9/2026, 2:44:54 PM)

11.98

+0.52 (+4.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-27
Earnings (Next)04-28
Inst Owners20.99%
Inst Owner Change10.62%
Ins Owners11.47%
Ins Owner Change-2.41%
Market Cap7.91M
Revenue(TTM)N/A
Net Income(TTM)-21.96M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.65%
Min EPS beat(2)-15.55%
Max EPS beat(2)24.84%
EPS beat(4)3
Avg EPS beat(4)15.45%
Min EPS beat(4)-15.55%
Max EPS beat(4)36.56%
EPS beat(8)6
Avg EPS beat(8)15.09%
EPS beat(12)8
Avg EPS beat(12)8.48%
EPS beat(16)8
Avg EPS beat(16)-14.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.27
EV/EBITDA N/A
EPS(TTM)-20.12
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-26.12
FCFYN/A
OCF(TTM)-26.11
OCFYN/A
SpS0
BVpS44.62
TBVpS44.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.89%
ROE -74.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -8.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.12
Quick Ratio 13.12
Altman-Z -7.02
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)30.57%
Cap/Depr(5y)103.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1412.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2200%
EPS Next Y13.26%
EPS Next 2Y9.4%
EPS Next 3Y12.02%
EPS Next 5Y12.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.93%
OCF growth 3YN/A
OCF growth 5YN/A

ENVVENO MEDICAL CORP / NVNO FAQ

Can you provide the ChartMill fundamental rating for ENVVENO MEDICAL CORP?

ChartMill assigns a fundamental rating of 2 / 10 to NVNO.


What is the valuation status for NVNO stock?

ChartMill assigns a valuation rating of 0 / 10 to ENVVENO MEDICAL CORP (NVNO). This can be considered as Overvalued.


How profitable is ENVVENO MEDICAL CORP (NVNO) stock?

ENVVENO MEDICAL CORP (NVNO) has a profitability rating of 0 / 10.


How financially healthy is ENVVENO MEDICAL CORP?

The financial health rating of ENVVENO MEDICAL CORP (NVNO) is 7 / 10.


What is the earnings growth outlook for ENVVENO MEDICAL CORP?

The Earnings per Share (EPS) of ENVVENO MEDICAL CORP (NVNO) is expected to grow by 13.26% in the next year.